DIRS.INFO The most relevant business & tech news

☆ Here are Monday's biggest analyst calls: Nvidia, Netflix, Tesla, Roku, Moderna, CVS, Alphabet, Robinhood & more
▼ + stars: | 2024-11-18 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Monday's biggest calls on Wall Street: Oppenheimer reiterates Netflix as outperform Oppenheimer said the Jake Paul-Mike Tyson fight "demonstrates [the] ability for meaningful" live event viewership for Netflix. Goldman Sachs initiates Ingram Micro as buy Goldman said the IT solutions provider is well positioned. Goldman Sachs initiates Gatx as buy Goldman said it's bullish on the railcar company. Baird upgrades Roku to outperform from neutral Baird said in its upgrade of Roku that it sees an "attractive long-term opportunity." Needham upgrades Robin Hood to buy from hold Needham said the stock is a beneficiary of the Trump election.

Persons: Oppenheimer, Jake Paul, Mike Tyson, it's bullish, Goldman Sachs, Ingram, Goldman, Baird, Morgan Stanley, Raymond James, Wells, Needham, Biogen, it's, Robin Hood, Trump, Donald Trump's, Bernstein, Tesla Organizations: Netflix, Citi, Astera, Ingram, GATX Corporation, RBC, UBS, Franco, Wheaton Precious Metals, WPM, HSBC, Moderna, Air Products, Hewlett Packard Enterprise, Enterprise, Aetna, Bank of America, Nvidia, " Bank of America, DOJ, Google, BMO, SEC, EV Locations: Nevada, Asia

☆ Stocks making the biggest moves midday: Moderna, Roku, CVS Health, Robinhood and more
▼ + stars: | 2024-11-18 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Trump Media & Technology Group — Shares in President-elect Donald Trump's media company pulled back roughly 5%. Although the stock has been increasingly volatile in the wake of Trump's election, it has gained more than 52% in 2024. Redfin — The online real estate company's stock slipped 3.4% following a downgrade at Goldman Sachs to sell from neutral. CVS Health — Shares of the drugstore operator jumped nearly 6% following a decision to add four new board members in a deal with Glenview Capital. Moderna — Shares of the biotech company jumped more than 5% after HSBC upgraded the stock to buy from hold and said it views the stock as being undervalued.

Persons: Donald Trump's, Donald Trump, Chris Wright, Wright, Baird, Goldman Sachs, Wells, Needham, Piper Sandler, —, Alex Harring, Sean Conlon, Hakyung Kim, Pia Singh, Michelle Fox Organizations: Spirit Airlines —, Trump Media & Technology, Liberty Energy, Goldman, CVS, Glenview Capital, Aetna, U.S . Securities, Exchange, Nasdaq, Moderna —, HSBC, Warner Bros, —, National Basketball Association Locations: Wells Fargo

☆ Stocks making the biggest moves premarket: Lyft, SolarEdge, Qualcomm, Moderna and more
▼ + stars: | 2024-11-07 | by ( Brian Evans | ) www.cnbc.com time to read: +5 min

Lyft expects bookings in the current quarter of $4.28 billion to $4.35 billion, while analysts polled by FactSet expected $4.23 billion. SolarEdge — The solar panel inverter stock slipped more than 16% after a third-quarter revenue miss. SolarEdge reported revenue of $261 million, while analysts surveyed by LSEG were looking for $269 million. Third-quarter revenue surpassed Wall Street estimates, and the company expects fourth-quarter revenue of $256 million to $262 million, compared with an estimate of $260 million. Moderna — Shares rallied 7% after Moderna's third-quarter earnings and revenue topped expectations.

Persons: FactSet, SolarEdge, —, Zillow, Gilead, LSEG, Armour, Hershey, Samantha Subin, Hakyung Kim, Sarah Min Organizations: Arm, Wall, LSEG, FactSet, —, Qualcomm, Gilead Sciences, Hershey Locations: Gilead

☆ Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
▼ + stars: | 2024-11-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected. Before year end, the company plans to file for approval of its experimental "next-generation" Covid vaccine and combination shot targeting Covid and the flu. Moderna this year also expects to apply for expanded approval of its RSV vaccine, targeting high-risk adults ages 18 to 59. "I think the earlier launch and a steeper ramp drove a much higher sales number" for the Covid vaccine, Moderna CEO Stéphane Bancel said in an interview. Analysts had expected sales of $132 million for the RSV vaccine, according to estimates compiled by StreetAccount.

Persons: Moderna, Stéphane Bancel, Bancel, StreetAccount, mull Organizations: Moderna, LSEG, Merck, Research Locations: U.S, Union, Norway, Iceland, Qatar, Europe

☆ Cramer's Lightning Round: 'Buy more' Pfizer
▼ + stars: | 2024-09-17 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Pfizer's year-to-date stock performance. Stock Chart Icon Stock chart icon First Solar's year-to-date stock performance. Stock Chart Icon Stock chart icon Equity Residential's year-to-date stock performance. Stock Chart Icon Stock chart icon Moderna's year-to-date stock performance. Stock Chart Icon Stock chart icon Vertiv's year-to-date stock performance.

Persons: Powell Organizations: Pfizer, Equity, Powell Industries

(This is CNBC Pro's live coverage of Friday's analyst calls and Wall Street chatter. A biotech stock and an energy company were among the names being talked about by analysts on Friday. — Sean Conlon 6:19 a.m.: Pivotal says buy TKO Group A competitive media landscape could mean gains for TKO Group , according to Pivotal Research Group. TKO Group shares are up nearly 41% year to date. TKO YTD mountain TKO in 2024 — Sean Conlon 5:49 a.m.: JPMorgan downgrades Moderna to underweight JPMorgan sees a rocky road ahead for Moderna .

Persons: Raymond James, Srini Pajjuri, — Sean Conlon, Jeffrey Wlodarczak, Jessica Fye, Fye, it's, Ameet, Thakkar, he's, Fred Imbert Organizations: CNBC, JPMorgan, Moderna, BMO Capital Markets, GE Vernova, ARM, Research, JPMorgan downgrades Moderna, Food and Drug Administration, BMO, GE, General, Gas Power, General Electric Locations: Thursday's

☆ Stocks making the biggest moves midday: Moderna, Uber, Boeing, Adobe and more
▼ + stars: | 2024-09-13 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Oracle — The stock rose nearly 2% after the database software company raised its fiscal 2026 revenue outlook . Uber — Shares of the ride-sharing company advanced more than 5% following news that it plans to expand its partnership with Alphabet's Waymo . Adobe — Shares tumbled 9% after the software company issued weaker-than-expected guidance for the current quarter. Unity Software — Shares of the game engine company added nearly 7%. Discovery — Shares advanced about 9% after the media conglomerate entered an early renewal agreement with Charter Communications.

Persons: Kevin Clark, RH —, Gary Friedman, Alphabet's Waymo, Uber, Stifel, Biden, David Zaslav, —, Jesse Pound, Sean Conlon, Samantha Subin, Hakyung Kim Organizations: JPMorgan, Oracle, Aptiv, — Stock, Adobe, Boeing, Unity, Holdings, PDD Holdings, Redfin Corporation, Federal Reserve, U.S, Home, Warner Bros, —, Charter Communications, Discovery Locations: U.S, Austin , Texas, Atlanta, China

☆ Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027
▼ + stars: | 2024-09-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. The company aims to trim R&D spending to a range of $3.6 billion to $3.8 billion in 2027, down from an expected $4.8 billion at the end of this year, according to a release. Moderna also has five non-respiratory products across cancer, latent viruses and rare diseases that could be approved by 2027, according to the company's release. The company expects 2025 revenue to come in at $2.5 billion to $3.5 billion. From 2026 to 2028, Moderna expects a compounded annual growth rate of more than 25% as new products launch.

Persons: Moderna, Stephane Bancel, Leerink, Mani Foroohar, Foroohar, Michael Yee, Bancel Organizations: Moderna, CNBC, Jefferies Locations: New York, U.S

☆ Moderna CEO: Plans to file Covid and flu combo shot with FDA by the end of the year
▼ + stars: | 2024-09-12 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna CEO: Plans to file Covid and flu combo shot with FDA by the end of the yearStephane Bancel, Moderna CEO, joins 'Squawk Box' to discuss Moderna's recent stock performance, what could explain the stock's underperformance, and much more.

Persons: Stephane Bancel Organizations: Email Moderna, FDA, Moderna

☆ Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

It's Moderna's second-ever commercially available product after its Covid vaccine, which has seen demand plunge as the world emerges from the pandemic and relies less on protective shots and treatments. He added that "we've been having quite intense discussions with governments across Europe" to get Covid vaccine supply from Moderna. He is referring to the European Union's massive renegotiated Covid vaccine supply contract with Pfizer and its German partner BioNTech . Its shares are up nearly 20% this year on increasing confidence around its pipeline and messenger RNA platform, which is the technology used in its Covid vaccine and RSV shot. Moderna is also developing a stand-alone flu shot, a personalized cancer vaccine with Merck and shots for latent viruses, among other products.

Persons: It's Moderna's, Stephane Bancel, we've, Bancel, BioNTech, Moderna, I'm Organizations: Moderna Inc, Moderna, Pfizer, GSK, LSEG, Wall, Research, Merck Locations: Cambridge , Massachusetts, Europe, U.S, Moderna, Ukraine

☆ Stock market today: Indexes tank as data paints a negative picture for the economy
▼ + stars: | 2024-08-01 | by ( Kelly Cloonan | ) www.businessinsider.com time to read: +2 min

US stocks nosedived on Thursday after several discouraging economic data points. The ISM manufacturing index dropped from 48.5% in June to 46.8% in July, marking an eight-month low. Investors are pricing in a 100% chance of Fed rate cuts in September, according to the CME FedWatch tool. Meanwhile, new data shows ISM manufacturing slid further into contraction territory in July. Jensen Huang just got $12 billion richer in a single day as Nvidia's stock soared on Wednesday.

Persons: —, Jerome Powell, Jensen Huang Organizations: Service, Reuters

☆ Moderna stock tumbles 21% as earnings show people aren't getting as many COVID shots
▼ + stars: | 2024-08-01 | by ( Kelly Cloonan | ) www.businessinsider.com time to read: +2 min

Moderna lowered its annual sales forecast as sales of its COVID-19 vaccine dropped by 37%. The company's vaccine sales struggled especially in Europe, where Pfizer has a deal until 2026. AdvertisementPeople are getting fewer COVID-19 shots, and it's hitting former vaccine heavyweight Moderna, new earnings show. The company's second quarter revenue dropped to $241 million, compared to $344 million a year ago, as sales of its COVID-19 vaccine dropped 37% year-over-year. Moderna also lowered its sales forecast for the year to between $3 billion and $3.5 billion, down from its previous forecast of around $4 billion.

Persons: —, it's, Stephane Bancel Organizations: Moderna, Pfizer, Service Locations: Europe, Moderna, Covid

☆ Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
▼ + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. Moderna's messenger RNA combination shot, called mRNA-1083, is made up of both the company's vaccine candidate for seasonal influenza and a newer, "next-generation" version of its Covid shot. The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna's currently licensed Covid shot, Spikevax, in one group of patients ages 65 and above. Moderna is also developing a combination shot targeting the flu and RSV, and another vaccine targeting all three respiratory viruses: Covid, flu and RSV. Meanwhile, Pfizer and BioNTech also are studying a vaccine that targets both Covid and the flu in a late-stage trial.

Persons: Stephane Bancel, Novavax, Bancel, Moderna, BioNTech Organizations: Pfizer, Novavax, Moderna, Covid Locations: U.S

☆ CNBC Daily Open: Opec extends cuts, Nvidia showcases new chip
▼ + stars: | 2024-06-03 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. OPEC+ extends cutsOPEC and it allies agreed to extend official crude production cuts into 2025 amid lackluster demand. Saudi Arabia's energy minister Prince Abdulaziz bin Salman said OPEC+ wants concrete rate cuts before factoring in the potential impact on energy demand. New AI chip RubinNvidia unveiled its next generation artificial intelligence chip, Rubin, a mere three months after launching its Blackwell model.

Persons: Prince Abdulaziz bin Salman, Rubin, Blackwell, Dow, UnitedHealth, Bill Ackman, It's, Michael Khouw Organizations: CNBC, Saudi Aramco, Rubin Nvidia, AMD, Intel, Microsoft, Google, Dow Jones, Federal, Dow, Nasdaq, Nvidia, Tesla, Pershing, Moderna, Drug Administration, GSK, Pfizer Locations: OPEC, Saudi Arabia, Russia, Saudi, U.S, Moderna

☆ Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
▼ + stars: | 2024-06-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society. Moderna is also conducting another phase three trial of the vaccine in patients with a type of lung cancer. This year, Merck and Moderna started a two-part mid- to late-stage trial on the vaccine and Keytruda in patients at an advanced stage of a common skin cancer.

Persons: Merck's, Kyle Holen, Keytruda, Stephane Bancel, Bancel Organizations: Moderna, Merck, American Society of Clinical Oncology, CNBC, U.S . Food, Drug Administration, FDA, American Cancer Society Locations: Chicago, U.S, Moderna

☆ FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
▼ + stars: | 2024-05-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Food and Drug Administration on Friday approved Moderna's vaccine for respiratory syncytial virus for adults ages 60 and above, the company's second-ever product to enter the U.S. market. The approval of Moderna's shot is based on a late-stage trial on older adults, who are more vulnerable to severe cases of RSV. The company's shot is also the only RSV vaccine to be available in a pre-filled syringe, which is designed to make it easier to administer to patients. An advisory panel to the CDC will vote in June on recommendations for the use and intended population of Moderna's shot. Moderna's full-year 2024 sales guidance of roughly $4 billion includes revenue from its RSV vaccine.

Persons: Moderna's, Stéphane Bancel Organizations: Drug Administration, Moderna, Centers for Disease Control, CDC, GSK, Pfizer Locations: U.S

☆ Cramer's Lighting Round: Sell AMC
▼ + stars: | 2024-05-24 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Moderna's year-to-date stock performance. Stock Chart Icon Stock chart icon Comfort Systems' year-to-date stock performance. Stock Chart Icon Stock chart icon Sunoco's year-to-date stock performance. Stock Chart Icon Stock chart icon Celestica's year-to-date stock performance. Stock Chart Icon Stock chart icon AMC Entertainment's year-to-date stock performance.

Organizations: Comfort Systems, AMC, AMC Entertainment, Systems, Inspire Medical

☆ Moderna says FDA delayed RSV vaccine approval to end of May
▼ + stars: | 2024-05-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end of May due to "administrative constraints" at the agency. The FDA was expected to make a decision on the RSV shot on Sunday. If cleared, the RSV shot would become the company's second product to launch in the U.S. after its once-blockbuster Covid vaccine. It would also be the third RSV vaccine to enter the market after shots from Pfizer and GSK rolled out last year. Moderna said its RSV vaccine is still on track to be reviewed by an advisory panel to the Centers for Disease Control and Prevention during a meeting on June 26 and 27.

Persons: Stephen Hoge Organizations: Moderna, Food and Drug Administration, FDA, Pfizer, GSK, Centers for Disease Control Locations: U.S

☆ Moderna first quarter cost of sales correction
▼ + stars: | 2024-05-02 | by ( ) www.cnbc.com time to read: 1 min

Moderna's cost of sales was $96 million for the first quarter. An earlier version misstated the time period.

☆ Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
▼ + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The biotech company booked first-quarter sales of $167 million, with revenue from its Covid shot dropping roughly 90% from the same period a year ago. The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from its RSV vaccine. For the first quarter, Mock said the company is "more encouraged by what we're seeing from a productivity perspective" than the higher sales of its Covid vaccine. Cost of sales was $96 million for the fourth quarter, down 88% from the same period a year ago.

Persons: we've, Stéphane Bancel, Jamey Mock, Mock, OpenAI Organizations: Moderna, LSEG, CNBC, Research, Mock, Merck Locations: Moderna, U.S, America

☆ Dr. Scott Gottlieb on the AI drug revolution, bird flu cattle outbreak latest
▼ + stars: | 2024-04-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Scott Gottlieb on the AI drug revolution, bird flu cattle outbreak latestFormer FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of Moderna's partnership with OpenAI to expand its employees access to AI chatbots, impact of the AI drug revolution, Dr. Gottlieb's venture into AI, latest developments on the bird flu cattle outbreak, and more.

Persons: Scott Gottlieb, OpenAI Organizations: FDA

☆ Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
▼ + stars: | 2024-04-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Thursday said it has paused plans to build a vaccine-manufacturing site in Kenya after a steep drop in demand for its Covid vaccines. Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine-manufacturing footprint. Moderna also had plans to start filling doses of its Covid vaccine in the continent as early as 2023. But the company has since determined that demand in Africa "is insufficient to support the viability of the factory planned in Kenya," Moderna said in a statement on Thursday. "This approach will allow Moderna to better align its infrastructure investments with the evolving healthcare needs and vaccine demand in Africa."

Persons: Moderna Organizations: Moderna, Kenyan Locations: Kenya, Africa

☆ Stocks making the biggest moves midday: Boeing, Norfolk Southern, Nvidia & more
▼ + stars: | 2024-04-09 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

BlackBerry — BlackBerry shares popped more than 9% after the company announced a partnership with Advanced Micro Devices on robotics systems. Neogen Corp — The food safety stock shed 9% after the company reported a surprise loss of 1 cent per share. The company also trimmed its previous guidance, saying it now expects revenue to range between $920 million and $910 million for the full year. Norfolk Southern announced that it reached a $600 million settlement related to its derailment in East Palestine. Nvidia — Shares fell more than 2%, putting the chipmaker on track for its fifth losing session in six.

Persons: Tilray, FactSet, Goldman Sachs, Molson Coors, Molson, — CNBC's Michelle Fox, Sarah Min, Pia Singh, Yun Li Organizations: Moderna, Reuters, Merck, Boeing, New York Times, Google, American Eagle Outfitters, JPMorgan, Eagle Outfitters, Bank of America, EV, Molson, Pfizer, Neogen Corp, Norfolk Southern, Nvidia —, Netflix Locations: East Palestine

☆ Moderna CEO on vaccines pipeline: Investing aggressively to bring important medicine to patients
▼ + stars: | 2024-03-27 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna CEO on vaccines pipeline: Investing aggressively to bring important medicine to patientsModerna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's annual vaccines day, the announcement of multiple vaccine programs advancing to late-stage clinical trials, Moderna's vaccines pipeline outlook, and more.

Persons: Stephane Bancel Organizations: Email Moderna

☆ Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
▼ + stars: | 2024-03-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna has more to offer beyond its Covid vaccine. The update brings Moderna a step closer to having multiple products on the market, which it badly needs amid plunging demand for Covid shots worldwide. Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor event in Boston focused on the company's vaccine portfolio. That includes its combination vaccine against Covid and the flu and a shot against another common herpes virus called cytomegalovirus, or CMV. It also includes a new and improved version of Moderna's Covid shot.

Persons: norovirus, Barr, Moderna, Blackstone, Stéphane Bancel Organizations: Moderna, Epstein, Covid, Blackstone Life Sciences, Blackstone Group Locations: Boston, U.S

Search resuls for: "Moderna's"

25 mentions found